![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Remdesivir Trials in China Suspended Due to Recruitment Issues
Remdesivir Trials in China Suspended Due to Recruitment Issues
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/China_Map.gif?t=1478215210&width=430)
April 16, 2020
Two phase 3 trials in China of Gilead’s remdesivir as a COVID-19 treatment have been suspended because of the lack of eligible patients.
One trial in adults with severe COVID-19 only enrolled 237 patients, just over half of its 452-enrollment target. The second trial for mild-to-moderate cases aimed to enroll 308 patients but fell short of that number.
Both trials began in February and were suspended on April 10, weeks before their anticipated close-out dates. Results of the trials have not yet been posted.
Upcoming Events
-
21Oct